Resistance to Oncolytic Myxoma Virus Therapy in Nf1-/-/Trp53-/- Syngeneic Mouse Glioma Models Is Independent of Anti-Viral Type-I Interferon

Franz J. Zemp, Brienne A. McKenzie, Xueqing Lun, Lori Maxwell, Karlyne M. Reilly, Douglas McFadden, V. Wee Yong, Peter A. Forsyth

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Despite promising preclinical studies, oncolytic viral therapy for malignant gliomas has resulted in variable, but underwhelming results in clinical evaluations. Of concern are the low levels of tumour infection and viral replication within the tumour. This discrepancy between the laboratory and the clinic could result from the disparity of xenograft versus syngeneic models in determining in vivo viral infection, replication and treatment efficacy. Here we describe a panel of primary mouse glioma lines derived from Nf1+/-Trp53+/- mice in the C57Bl/6J background for use in the preclinical testing of the oncolytic virus Myxoma (MYXV). These lines show a range of susceptibility to MYXV replication in vitro, but all succumb to viral-mediated cell death. Two of these lines orthotopically grafted produced aggressive gliomas. Intracranial injection of MYXV failed to result in sustained viral replication or treatment efficacy, with minimal tumour infection that was completely resolved by 7 days post-infection. We hypothesized that the stromal production of Type-I interferons (IFNα/β) could explain the resistance seen in these models; however, we found that neither the cell lines in vitro nor the tumours in vivo produce any IFNα/β in response to MYXV infection. To confirm IFNα/β did not play a role in this resistance, we ablated the ability of tumours to respond to IFNα/β via IRF9 knockdown, and generated identical results. Our studies demonstrate that these syngeneic cell lines are relevant preclinical models for testing experimental glioma treatments, and show that IFNα/β is not responsible for the MYXV treatment resistance seen in syngeneic glioma models.

Original languageEnglish (US)
Article numbere65801
JournalPLoS One
Volume8
Issue number6
DOIs
StatePublished - Jun 6 2013
Externally publishedYes

Fingerprint

Myxoma virus
Oncolytic Virotherapy
Interferon Type I
interferons
Viruses
Glioma
Tumors
Interferons
therapeutics
neoplasms
mice
infection
Virus Diseases
Neoplasms
virus replication
Infection
Cells
cell lines
Oncolytic Viruses
Cell Line

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Resistance to Oncolytic Myxoma Virus Therapy in Nf1-/-/Trp53-/- Syngeneic Mouse Glioma Models Is Independent of Anti-Viral Type-I Interferon. / Zemp, Franz J.; McKenzie, Brienne A.; Lun, Xueqing; Maxwell, Lori; Reilly, Karlyne M.; McFadden, Douglas; Yong, V. Wee; Forsyth, Peter A.

In: PLoS One, Vol. 8, No. 6, e65801, 06.06.2013.

Research output: Contribution to journalArticle

Zemp, Franz J. ; McKenzie, Brienne A. ; Lun, Xueqing ; Maxwell, Lori ; Reilly, Karlyne M. ; McFadden, Douglas ; Yong, V. Wee ; Forsyth, Peter A. / Resistance to Oncolytic Myxoma Virus Therapy in Nf1-/-/Trp53-/- Syngeneic Mouse Glioma Models Is Independent of Anti-Viral Type-I Interferon. In: PLoS One. 2013 ; Vol. 8, No. 6.
@article{eec050e95d114bd9b340739c25607b8e,
title = "Resistance to Oncolytic Myxoma Virus Therapy in Nf1-/-/Trp53-/- Syngeneic Mouse Glioma Models Is Independent of Anti-Viral Type-I Interferon",
abstract = "Despite promising preclinical studies, oncolytic viral therapy for malignant gliomas has resulted in variable, but underwhelming results in clinical evaluations. Of concern are the low levels of tumour infection and viral replication within the tumour. This discrepancy between the laboratory and the clinic could result from the disparity of xenograft versus syngeneic models in determining in vivo viral infection, replication and treatment efficacy. Here we describe a panel of primary mouse glioma lines derived from Nf1+/-Trp53+/- mice in the C57Bl/6J background for use in the preclinical testing of the oncolytic virus Myxoma (MYXV). These lines show a range of susceptibility to MYXV replication in vitro, but all succumb to viral-mediated cell death. Two of these lines orthotopically grafted produced aggressive gliomas. Intracranial injection of MYXV failed to result in sustained viral replication or treatment efficacy, with minimal tumour infection that was completely resolved by 7 days post-infection. We hypothesized that the stromal production of Type-I interferons (IFNα/β) could explain the resistance seen in these models; however, we found that neither the cell lines in vitro nor the tumours in vivo produce any IFNα/β in response to MYXV infection. To confirm IFNα/β did not play a role in this resistance, we ablated the ability of tumours to respond to IFNα/β via IRF9 knockdown, and generated identical results. Our studies demonstrate that these syngeneic cell lines are relevant preclinical models for testing experimental glioma treatments, and show that IFNα/β is not responsible for the MYXV treatment resistance seen in syngeneic glioma models.",
author = "Zemp, {Franz J.} and McKenzie, {Brienne A.} and Xueqing Lun and Lori Maxwell and Reilly, {Karlyne M.} and Douglas McFadden and Yong, {V. Wee} and Forsyth, {Peter A.}",
year = "2013",
month = "6",
day = "6",
doi = "10.1371/journal.pone.0065801",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Resistance to Oncolytic Myxoma Virus Therapy in Nf1-/-/Trp53-/- Syngeneic Mouse Glioma Models Is Independent of Anti-Viral Type-I Interferon

AU - Zemp, Franz J.

AU - McKenzie, Brienne A.

AU - Lun, Xueqing

AU - Maxwell, Lori

AU - Reilly, Karlyne M.

AU - McFadden, Douglas

AU - Yong, V. Wee

AU - Forsyth, Peter A.

PY - 2013/6/6

Y1 - 2013/6/6

N2 - Despite promising preclinical studies, oncolytic viral therapy for malignant gliomas has resulted in variable, but underwhelming results in clinical evaluations. Of concern are the low levels of tumour infection and viral replication within the tumour. This discrepancy between the laboratory and the clinic could result from the disparity of xenograft versus syngeneic models in determining in vivo viral infection, replication and treatment efficacy. Here we describe a panel of primary mouse glioma lines derived from Nf1+/-Trp53+/- mice in the C57Bl/6J background for use in the preclinical testing of the oncolytic virus Myxoma (MYXV). These lines show a range of susceptibility to MYXV replication in vitro, but all succumb to viral-mediated cell death. Two of these lines orthotopically grafted produced aggressive gliomas. Intracranial injection of MYXV failed to result in sustained viral replication or treatment efficacy, with minimal tumour infection that was completely resolved by 7 days post-infection. We hypothesized that the stromal production of Type-I interferons (IFNα/β) could explain the resistance seen in these models; however, we found that neither the cell lines in vitro nor the tumours in vivo produce any IFNα/β in response to MYXV infection. To confirm IFNα/β did not play a role in this resistance, we ablated the ability of tumours to respond to IFNα/β via IRF9 knockdown, and generated identical results. Our studies demonstrate that these syngeneic cell lines are relevant preclinical models for testing experimental glioma treatments, and show that IFNα/β is not responsible for the MYXV treatment resistance seen in syngeneic glioma models.

AB - Despite promising preclinical studies, oncolytic viral therapy for malignant gliomas has resulted in variable, but underwhelming results in clinical evaluations. Of concern are the low levels of tumour infection and viral replication within the tumour. This discrepancy between the laboratory and the clinic could result from the disparity of xenograft versus syngeneic models in determining in vivo viral infection, replication and treatment efficacy. Here we describe a panel of primary mouse glioma lines derived from Nf1+/-Trp53+/- mice in the C57Bl/6J background for use in the preclinical testing of the oncolytic virus Myxoma (MYXV). These lines show a range of susceptibility to MYXV replication in vitro, but all succumb to viral-mediated cell death. Two of these lines orthotopically grafted produced aggressive gliomas. Intracranial injection of MYXV failed to result in sustained viral replication or treatment efficacy, with minimal tumour infection that was completely resolved by 7 days post-infection. We hypothesized that the stromal production of Type-I interferons (IFNα/β) could explain the resistance seen in these models; however, we found that neither the cell lines in vitro nor the tumours in vivo produce any IFNα/β in response to MYXV infection. To confirm IFNα/β did not play a role in this resistance, we ablated the ability of tumours to respond to IFNα/β via IRF9 knockdown, and generated identical results. Our studies demonstrate that these syngeneic cell lines are relevant preclinical models for testing experimental glioma treatments, and show that IFNα/β is not responsible for the MYXV treatment resistance seen in syngeneic glioma models.

UR - http://www.scopus.com/inward/record.url?scp=84878811622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878811622&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0065801

DO - 10.1371/journal.pone.0065801

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e65801

ER -